Munich - Delayed Quote EUR

Achilles Therapeutics plc (698.MU)

Compare
1.3600
0.0000
(0.00%)
As of March 25 at 8:08:59 AM GMT+1. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Dr. Iraj Ali Ph.D. Chief Executive Officer 1.56M -- 1975
Dr. Sergio A. Quezada Ph.D. Founder -- -- 1976
Mr. Robert Coutts CFO & Director -- -- 1984
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. Founder & Member of Scientific Advisory Board -- -- 1963
Dr. Charles Swanton FMEDSCI, M.D., Ph.D. Founder & Member of Scientific Advisory Board -- -- 1972
Mr. Lee M. Stern Vice President of Investor Relations & External Communications -- -- --
Mr. Daniel Carey Cazel Hood General Counsel, Company Secretary & Director -- -- --
Julia Wilson Head of Communications -- -- --
Mr. Tariq Ahmed Executive Vice President of People -- -- --

Achilles Therapeutics plc

245 Hammersmith Road
London, W6 8PW
United Kingdom
44 20 8154 4600 https://www.achillestx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
204

Description

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Corporate Governance

Achilles Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

April 2, 2025 at 12:30 PM UTC - April 7, 2025 at 12:30 PM UTC

Achilles Therapeutics plc Earnings Date

Recent Events

Related Tickers